Why Contango Ore Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Shares of Contango Ore, Inc. (NYSE:CTGO) fell sharply during Tuesday’s session after the company announced pricing of $15…
12 Health Care Stocks Moving In Tuesday’s Intraday Session
Gainers Elutia (NASDAQ:ELUT) stock rose 24.2% to $4.31 during Tuesday’s regular session. The market value of their outstanding…
Why Calavo Growers Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Shares of Calavo Growers, Inc. (NASDAQ:CVGW) rose sharply in today’s pre-market trading after the company reported second-quarter financial…
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers Viracta Therapeutics (NASDAQ:VIRX) stock increased by 16.8% to $0.68 during Tuesday’s pre-market session. The company’s market cap…
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers Entero Therapeutics (NASDAQ:ENTO) stock rose 10.2% to $2.6 during Monday’s after-market session. The market value of their…
ProKidney Announces Operational Updates and Progress in European and US Clinical Trials for CKD Therapy, Rilparencel
ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced positive interim results from the Phase 2
12 Health Care Stocks Moving In Tuesday’s Intraday Session
Gainers Delcath Systems (NASDAQ:DCTH) stock rose 33.2% to $7.19 during Tuesday’s regular session. The company’s market cap stands…
12 Health Care Stocks Moving In Monday’s Intraday Session
Gainers NKGen Biotech (NASDAQ:NKGN) shares rose 33.8% to $1.48 during Monday’s regular session. The company’s market cap stands…
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers Trevena (NASDAQ:TRVN) shares increased by 27.0% to $0.51 during Wednesday’s after-market session. The company’s market cap stands…
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.